Innate Pharma (IPH.PA ) : Start Of Cohort Expansion Of Phase I Trial With Lirilumab And Nivolumab In Selected Solid Tumors
3/31/2014 10:08:44 AM
MARSEILLE, France, March 31, 2014 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the start of the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab (anti-KIR) and nivolumab (anti-PD-1) in selected solid tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by